Skip to content
Screener

Whitehawk Therapeutics WHWK Q1 2025 earnings

Reported May 8, 2025 · Before market open

Revenue$7.1M
EPS-$0.36Beat by $0.10
EPS estimate-$0.46

Next report

Nov 5, 2026 (in 2 months)
EPS estimate-$0.27

Financials

Q1 2025

Income statement

See full
Revenue$7.1M+33.5%
Gross profit$6.4M+35.8%
Operating income-$15.2M+22.0%
Net income$73.0M+499%
EPS (diluted)$1.83+369%

Balance sheet

See full
Cash & equivalents$227.6M+323%
Total equity$221.7M+145%
Total assets$234.0M+111%

Cash flow

See full
Operating cash flow-$11.9M+39.6%
CapEx$551.0K-25.4%
Free cash flow-$12.4M+39.1%

Valuation & ratios

Profitability

See full
Gross margin88.7%+1.0pp
Operating margin-227.4%-48.8pp
Net margin99.4%+57.0pp
FCF margin-191.6%-39.0pp

Returns & leverage

See full
Return on equity17.7%+10.0pp
Current ratio19×+13.8×

Segments

By segment

See full
Reportable$7.1M+33.5%

FAQ

When did Whitehawk Therapeutics report Q1 2025 earnings?
Whitehawk Therapeutics (WHWK) reported Q1 2025 earnings on May 8, 2025 before market open.
What were Whitehawk Therapeutics's Q1 2025 revenue and EPS?
Whitehawk Therapeutics reported revenue of $7.1M and eps of $-0.36 for Q1 2025.
Did Whitehawk Therapeutics beat estimates in Q1 2025?
EPS beat the consensus estimate of $-0.46 by $0.10.
Where can I find Whitehawk Therapeutics's Q1 2025 SEC filings?
You can read the 8-K earnings release (0001628280-25-023788) and the 10-Q periodic report (0001628280-25-023932) directly on SEC EDGAR. The filing index links above go to sec.gov.